Let's just have the sublime ESO video do the 'splainin', shall we? [She's been named "Oumuamua", by her discoverers -- which translates from the native Hawaiian as "first arriving messenger, from afar".] Yes. . . let's. See below.
It is highly unlikely that this object will ever see her arc bend backward, and twist, toward our sun again -- she is passing through our lives but once. Like so many odd, yet preciously graceful, things. . . indeed.
. . . .Astronomers have recently studied an asteroid that has entered the Solar System from interstellar space. Observations from ESO’s Very Large Telescope in Chile (and other observatories around the world) prove that this unique object was travelling through interstellar space for millions of years before its chance encounter with our star system. It appears to be a darkly reddish (red-bone!), highly-elongated, high-metal-content object. . . .
As ever -- the idea of a dusky metallic visitor -- from near the "time, before time". . . at least relative to our own local group. . . fires my imagination. No doubt (being a man of science, after all!), under this graceful, roughly Mount Blanc pen-shaped metal, are the vestiges of one or more timeless raindrops -- and under those raindrops, are the words -- and some of those words, are mine to you. Travel well -- and do travel light.
नमस्ते
2 comments:
on a different note but, related to Merck: https://www.cbsnews.com/news/a-vioxx-comeback-a-startup-eyes-the-drug-for-hemophilia/
Indeed. Given the 75 or so posts we've put up over the past nine years, related to Vioxx -- and its checkered safety profile. . .
I personally think this is a pretty dubious idea. It is particularly odd that a former Merck sales guy, who helped pull rofecoxib from shelves in 2004, would think it a good idea.
But -- God bless America -- there is a new generation out there, organizing all sorts of start up ideas. I cannot imagine how a retooled Vioxx would fit in the engineered blood factor protein market, now dominated by the likes of Shire (formerly a Baxter line), Amgen and so on -- in short, I think the world has moved on -- and a pain med that may not be cardio-safe (but doesn't cause internal bleeding) seems to be a not-so-great trade off.
Let's see whether Mr. Sippy can raise the $25 million to run his trial -- the capital markets will be a fair and unbiased gauge of whether a generic rofecoxib can hit an orphan drug goal here.
Thanks so much -- and do have a great Thanksgiving, Anon.
I'm out until Monday night, after a quick Merck real estate update, forthcoming.
Namaste. . . .
Post a Comment